Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in Diabetes

Journal Scan / Research · April 06, 2017

Semaglutide Once-Weekly Bests Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes

The Lancet Diabetes & Endocrinology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Janet McGill MD

The Lancet Diabetes & Endocrinology
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin (With or Without Sulfonylureas) in Insulin-Naive Patients With Type 2 Diabetes (SUSTAIN 4): A Randomised, Open-Label, Parallel-Group, Multicentre, Multinational, Phase 3a Trial
Lancet Diabetes Endocrinol 2017 Mar 23;[EPub Ahead of Print], VR Aroda, SC Bain, B Cariou, M Piletič, L Rose, M Axelsen, E Rowe, JH DeVries

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated